Predictive Value of Baseline Plasma D-dimers for Chemotherapy-induced Thrombocytopenia in Patients with Stage III Colon Cancer: A Pilot Study

  • Tanriverdi, Ozgur (Department of Medical Oncology, Mugla Sitki Kocman University Education and Research Hospital)
  • Published : 2013.01.31


Background: : Chemotherapy-induced thrombocytopenia (CIT) is an important cause of morbitity in patients with cancer. Aim: To investigate the effect of the baseline plasma D-dimer level, an important marker for thrombotic activity, on chemotherapy-induced thrombocytopenia in patients with stage III colon cancer. Materials and Methods: A total of 43 (28 men) eligible patients were divided into two groups according to whether they exhibited chemotherapy-induced thrombocytopenia: Group 1 (n=21) and Group 2 (n=22). Comparison was made using demographic, histopathologic, and laboratory variables. Additionally, baseline plasma D-dimer levels underwent receiver operation characteristics curve analysis, and areas under the curve were calculated. Sensitivity, specificity, and positive and negative likelihood rates were then determined. Results: The incidence of chemotherapy-induced thrombocytopenia had a significant correlation with baseline platelet count (r=0.568, P=0.031) and baseline plasma D-dimer levels (r=0.617, P=0.036). When the cut-off point for the latter was set as 498 ng/mL, the area under the curve was 0.89 (95%CI: 0.74-0.93), the sensitivity was 91.4%, the specificity was 89.7%, the positive likelihood rate was 3.64 and the negative likelihood rate was 0.24 for chemotherapy-induced thrombocytopenia diagnosis. Conclusions: The baseline level of plasma D-dimer could help to differentiate high-risk patients for chemotherapy-induced thrombocytopenia.


  1. Komurcuoglu B, Ulusoy S, Gayaf M, et al (2011). Prognostic value of plasma D-dimer levels in lung carcinoma. Tumori, 97, 743-8.
  2. Levin RD, Daehler MA, Grutsch JF, et al (2010). Dose escalation study of an anti-thrombocytopenic agent in patients with chemotherapy induced thrombocytopenia. BMC Cancer, 10, 565-72.
  3. Oya M, Akiyama Y, Okuyama T, Ishikawa H (2001). High preoperative plasma D-dimer level is associated with advanced tumor stage and short survival after curative resection in patients with colorectal cancer. Jpn J Clin Oncol, 31, 388-94.
  4. Sekhon SS, Roy V (2006). Thrombocytopenia in adults: a practical approach to evaluation and management. South Med J, 99, 491-8.
  5. Ten Berg MJ, van den Bent PM, Shantakumar S, et al (2011). Thrombocytopenia in adult cancer patients receiving cytotoxic chemotherapy: results from a retrospective hospital-based cohort study. Drug Saf, 34, 1151-60.
  6. Wu S, Zhang Y, Xu L, et al (2012). Multicenter, randomized study of genetically modified recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in cancer patients receiving chemotherapy. Support Care Cancer, 20, 1875-84
  7. Yamamato M, Yoshinaga K, Matsuyama A, et al (2012). Plasma D-dimer level as a mortality predictor in patients with advanced or recurrent colorectal cancer. Oncology, 83, 10-5.
  8. Yashiki C, Hirose T, Sugiyama T, et al (2010). Chemotherapyinduced myelosuppression and treatment efficacy in limitedstage disease small cell lung cancer. Gan To Kagaku Ryoho, 37, 245-9.
  9. Antoniou D, Pavlakou G, Stathopoulos GP, et al (2006). Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer. Lung Cancer, 53, 205-10.
  10. Arnold DM, Lim W (2011). A rational approach to the diagnosis and management of thrombocytopenia in the hospitalized patient. Semin Hematol, 48, 251-8.
  11. Andre T, Boni C, Mounedji-Boudiaf L (2004). Oxaliplatin, fluorouracil, and leucovorin an adjuvant treatment for colon cancer. N Engl J Med, 350, 2343-52.
  12. Bartucci M, Dattilo R, Martinetti D, et al (2011). Prevention of chemotherapy-induced anemia and thrombocytopenia by constant administration of stem cell factor. Clin Cancer Res, 17, 6185-91.
  13. Blackwell K, Haroon Z, Broadwater G, et al (2000). Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. J Clin Oncol, 18, 600-8.
  14. Colucci G, Gebbia V, Paoletti G, et al (2005). Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the gruppo oncologica dell'italia meridionale. J Clin Oncol, 23, 4866-75.
  15. Dirix LY, Salgado R, Weytjens R, et al (2002). Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer, 86, 389-95.
  16. Edwards CM, Warren J, Armstrong L, Donnelly PK (1993). D-dimer: a useful marker of disease stage in surgery for colorectal cancer. Br J Surg, 80, 1404-5.
  17. Hitron A, Steinke D, Sutphin S, et al (2011). Incidence and risk factors of clinically significant chemotherapy-induced thrombocytopenia in patients with solid tumors. J Oncol Pharm Pract, 17, 312-9.
  18. Jelic S, Radulovic S (2006). Chemotherapy-associated thrombocytopenia: current and emerging management strategies. Am J Cancer, 6, 372-82.
  19. Kirwan CC, McDowell G, McCollum CN, Kumar S, Byrne GJ (2008). Early changes in the haemostatic and procoagulant systems after chemotherapy for breast cancer. Br J Cancer, 99, 1000-6.

Cited by

  1. Malignancies and Disseminated Intravascular Coagulation vol.14, pp.7, 2013,
  2. Is there any effect of lower extremity deep vein thrombosis which proven by Doppler ultrasonography on cancer recurrence in patients with stage III colon cancer? A study of the Turkish Descriptive Oncological Researches Group vol.31, pp.10, 2014,